Personal stories

Only one in three people with major depressive disorder achieves remission after their first antidepressant, leaving many to continue to experience life-impacting symptoms such as disrupted sleep, changes in weight and appetite and trouble concentrating. Learn why Johnson & Johnson is working to help more patients achieve remission.

Johnson & Johnson launched this competition with one goal: to accelerate the development of next-generation surgical technologies. Meet this year’s three awardees and learn about their innovations.

Learn about one employee’s very personal mission to help restore vision for people who undergo cataract surgery.

Check out this infographic breakdown of the company’s second-quarter performance, with highlights from its Innovative Medicine and MedTech businesses.

A Johnson & Johnson scientist explains how the Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.

Once considered a straightforward procedure to restore cloudy vision, cataract surgery has evolved into one of the most technologically advanced—and personalized—operations in modern medicine. Learn how Johnson & Johnson’s 25-year history of innovation is helping eye surgeons meet the moment.

The company’s ability to evolve as it tackles the world’s toughest health challenges has helped Johnson & Johnson earn its spot as the top-ranked healthcare company on the list.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.